ROR1 and B-cell chronic lymphocytic leukemia: UC-961 (cirmtuzumab) is the first humanized mAb targeting ROR1 in CLL [42], and clinical trials of single or combination therapy with other agents are ongoing (NCT03088878, NCT02860676, NCT04501939, and NCT02776917).